Previously announced partnership with Tollo Health subsidiary TolloCare adding telehealth service offering to drive Wellgistics Pharmacy prescription drug dispending of GLP-1 drugs and promote patient engagement via mental health AI software solution for compliance and to promote lifestyle changes TAMPA, FL / ACCESS Newswire / February 18, 2026 / Wellgistics Health, Inc. (NASDAQ:WGRX), a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence (' ...

Core Insights - The article discusses the strategic partnership between Wellgistics Health, Inc. and DataVault AI, Inc. to enhance the PharmacyChain platform using advanced technologies [1] - The partnership aims to leverage DataVault AI's edge network and quantum key encryption to improve data-driven outcomes in the $634 billion prescription drug market [1] Company Overview - Wellgistics Health, Inc. is a leader in health information technology, focusing on pharmacy dispensing optimization through its AI platform EinsteinRx [1] - DataVault AI, Inc. specializes in AI-driven data valuation, monetization, and secure tokenization within Web 3.0 environments [1] Technology Integration - The partnership will integrate DataVault AI's advanced technology platform into Wellgistics' PharmacyChain, enhancing its blockchain-enabled smart contracts and tokenization capabilities [1] - Quantum key encryption will fortify pharmacies against potential threats from quantum computing, which could compromise traditional encryption methods [1]

Core Insights - Wellgistics Health, Inc. is integrating its AI platform EinsteinRx into pharmacy point-of-sales systems to enhance prescription drug dispensing efficiency [1] - The company aims to onboard up to 500 pharmacies per month into the Wellgistics Pharmacy Network by the end of 2026 [1] - The focus of the manufacturer-supplier relationship expansion is on diabetes, weight loss, cardiometabolic, and Long COVID patients [1] - Wellgistics is assessing resources for the development of blockchain-enabled smart contracts through its PharmacyChain platform [1] - The company is entering a phase of hyper-focused operational execution under the leadership of President and Interim-CEO Prashant Patel [1]

Core Insights - Wellgistics Health, Inc. has launched the diabetes prescription drug Brenzavvy® targeting 33 million Americans diagnosed with type II diabetes, primarily through its network of 6,500 independent pharmacies [1][4] - The SGLT-2 inhibitor market, which includes drugs like Jardiance®, reached sales of $16.8 billion in 2024 and is projected to grow to $28.9 billion by 2033, with the U.S. accounting for 40.8% of this market [2][4] - The proprietary EinsteinRx™ artificial intelligence platform will assist pharmacists in optimizing therapy selection and educating providers about Brenzavvy's benefits compared to other SGLT-2 inhibitors [2][3] Company Overview - Wellgistics Health integrates its EinsteinRx™ AI platform with a blockchain-enabled smart contracts platform, PharmacyChain™, to enhance the prescription drug dispensing process [4][5] - The company aims to improve patient access to medications while providing revenue opportunities for pharmacists through patient education on Brenzavvy [3][4] - The launch of Brenzavvy establishes a new model for next-generation drugs that offer specific advantages over established market leaders [4] Market Context - A significant gap exists in the prescription of SGLT-2 inhibitors, with only 11.9% of eligible diabetic patients receiving guideline-recommended prescriptions, indicating a need for improved care [2] - The launch of Brenzavvy is positioned to address the high out-of-pocket costs faced by many patients, particularly those who are uninsured or underinsured [4]

Core Viewpoint - Wellgistics Health, Inc. has announced a record date of December 19, 2025, for shareholders to receive the Dream Bowl 2026 Meme Coin, with one coin distributed for each share owned [1] Company Overview - Wellgistics Health, Inc. is a leader in health information technology, focusing on the implementation of EinsteinRx™ artificial intelligence for prescription drug routing [1] - The company utilizes a blockchain-enabled smart contracts platform, PharmacyChain™, to enhance the reimbursement and dispensing process for prescription medicines [1]

Group 1 - The company plans to distribute Dream Bowl 2026 Meme Coin to shareholders with a record date and distribution date expected in December 2025 [1] - Distribution of the Meme Coin is anticipated to occur in January 2026 [1] - Wellgistics Health, Inc. is involved in the DataVault AI Shareholder Distribution Plan and is sponsoring Dream Bowl 2026 [1] Group 2 - Wellgistics is a leader in health information technology, utilizing EinsteinRx™ artificial intelligence for prescription routing [1] - The company employs PharmacyChain™ blockchain-enabled smart contracts to enhance the tracking and dispensing of prescription drugs [1] - The technology aims to optimize insurance coverage from manufacturers to patients [1]

Core Insights - Wellgistics is positioned to lead in the Web 3.0 Health Information Data Transfer within the $634 billion prescription drug industry through an exclusive licensing agreement with Datavault AI [1][2][6] - The implementation of Wellgistics' EinsteinRx AI hub is expected to optimize automated prescription fulfillment for various stakeholders including manufacturers, pharmacies, and patients [1][4][6] - Datavault's intellectual property enables smart contracts that create a barrier to entry in the $4.9 trillion US healthcare market [1][2] Company Overview - Wellgistics Health, based in Tampa, Florida, specializes in optimizing medication delivery from manufacturers to patients, connecting over 6,500 pharmacies and 200 manufacturers [3][9] - The PharmacyChain initiative aims to digitize the tracking of prescription drugs, ensuring accurate delivery and recommendations for safe use [3][5] Technology and Innovation - The completion of the EinsteinRx AI hub integrates Wellgistics' IT and physical infrastructure, enhancing the efficiency of prescription fulfillment and reducing costs associated with pharmacy benefits managers (PBMs) [4][5][6] - Wellgistics aims to minimize or eliminate PBM rebates, thereby reducing administrative burdens for payers and improving the overall pharmaceutical distribution process [6][7] Market Potential - PwC estimates a $1 trillion opportunity to shift healthcare spending towards a digital-first, proactive, and personalized system [2] - The integration of smart contracts into Wellgistics' operations is expected to significantly improve cost efficiency in the prescription filling process, benefiting various stakeholders in the healthcare ecosystem [6][7]